DPP-4 Therapy Center - Diabetes In Control

Dapagliflozin vs. Saxagliptin: Durability of Glycemic Control

Dec 16, 2019 Paid, DPP-4 Therapy Center, SGLT-2 Therapy Center

The persistence of benefits of dapagliflozin over saxagliptin might change therapy choices in patients with type 2 diabetes.

New Approved Complete Diabetes Regimen in One Tablet

Nov 9, 2019 DPP-4 Therapy Center, Metformin Therapy Center, SGLT-2 Therapy Center

Diabetes has never been simpler to control with this once daily pill.

New Diabetes Medications Have Reduced Heart Failure Risk by 34 Percent

Oct 8, 2019 Cardiology, DPP-4 Therapy Center, SGLT-2 Therapy Center

Study examines SGLT-2 inhibitors versus DPP-4 in reducing cardiovascular events.

Phase 3 Comparison Trial: GLP-1 vs DPP-4

Sep 17, 2019 Type 2 Diabetes, DPP-4 Therapy Center, GLP-1 Agonist Therapy Center

A recent study demonstrates the efficacy of a new, once daily oral option for patients with type 2 diabetes already on metformin.

Liraglutide and Sitagliptin Useful for Nonalcoholic Fatty Liver Disease in T2DM

Aug 20, 2019 Type 2 Diabetes, DPP-4 Therapy Center, GLP-1 Agonist Therapy Center

A recent study reveals Liraglutide and Sitagliptin reduce intrahepatic lipid in patients with T2DM and IHL.

The CARMELINA Trial: Linagliptin’s Cardiovascular Effects for Type 2 Diabetes with High Cardiorenal Risk — ADA 2019

Jul 2, 2019 Type 2 Diabetes, Cardiology, Nephrology, DPP-4 Therapy Center

The CARMELINA trial demonstrated noninferiority of linagliptin compared with placebo in CV events in high risk people with type 2 diabetes.

Patients With T2D, Mild Renal Impairment Can Benefit From A DPP-4 Inhibitor

Aug 25, 2018 Type 2 Diabetes, Nephrology, Articles, DPP-4 Therapy Center

Sitagliptin showed greater glycemic efficacy over dapagliflozin when added onto existing therapy.

Dipeptidyl Peptidase-4 Inhibitors and Incidence of Inflammatory Bowel Disease

May 5, 2018 Articles, DPP-4 Therapy Center

Prolonged use of medication increases risk of bowel condition, but exact cause yet to be determined.

Understanding The Gap Between Efficacy In Randomized Trials And Effectiveness In Real-World Use Of GLP-1RA and DPP-4 Therapies

Jan 13, 2018 Type 2 Diabetes, Articles, DPP-4 Therapy Center

Patients are not seeing the expected results because of medication adherence.

Greater HbA1c Reduction with DPP4 Inhibitor, AGI Combination

Dec 16, 2017 Type 2 Diabetes, Articles, DPP-4 Therapy Center

Additive glucose-lowering effect of a dipeptidyl peptidase-4 (DPP4) inhibitor and an alpha-glucosidase inhibitor (AGI) might be beneficial in patients with T2DM.